1-3 of 3
Larissa S. Carnevalli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition

Available to Purchase
Larissa S. Carnevalli, Molly A. Taylor, Matthew King, Anna M.L. Coenen-Stass, Adina M. Hughes, Sigourney Bell, Theresa A. Proia, Yanjun Wang, Antonio Ramos-Montoya, Neha Wali, Danielle Carroll, Maneesh Singh, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Susan E. Critchlow, Teresa Klinowska, Stephen E. Fawell, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (6): 1080–1091.
https://doi.org/10.1158/1535-7163.MCT-20-0961
Published: 01 June 2021
View articletitled, Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition
Open the PDF for Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition in another window
Includes: Supplementary data
Journal Articles

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

Free
Nicolas Floc'h, Susan Ashton, Douglas Ferguson, Paula Taylor, Larissa S. Carnevalli, Adina M. Hughes, Emily Harris, Maureen Hattersley, Shenghua Wen, Nicola J. Curtis, James E. Pilling, Lucy A. Young, Kim Maratea, Elizabeth J. Pease, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (5): 909–919.
https://doi.org/10.1158/1535-7163.MCT-18-0577
Published: 01 May 2019
View articletitled, Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma
Open the PDF for Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

Free
Chrysiis Michaloglou, Claire Crafter, Rasmus Siersbaek, Oona Delpuech, Jon O. Curwen, Larissa S. Carnevalli, Anna D. Staniszewska, Urszula M. Polanska, Azadeh Cheraghchi-Bashi, Mandy Lawson, Igor Chernukhin, Robert McEwen, Jason S. Carroll, Sabina C. Cosulich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (5): 908–920.
https://doi.org/10.1158/1535-7163.MCT-17-0537
Published: 30 April 2018
View articletitled, Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
Open the PDF for Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer in another window
Includes: Supplementary data